Ultrase® MT20

DRUG2 trials

Sponsors

Forest Laboratories

Conditions

Cystic FibrosisExocrine Pancreatic InsufficiencyPancreatic Insufficiency

Phase 3

Safety and Efficacy Study of ULTRASE® MT20 in Participants With Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (PI)

CompletedNCT00408317

Forest LaboratoriesCystic Fibrosis, Exocrine Pancreatic Insufficiency

Start: 2006-11-30End: 2007-04-30Updated: 2017-03-16

Efficacy and Safety of Ultrase® MT20 in Improving the Coefficient of Fat Absorption (CFA) in Children With Cystic Fibrosis (CF) and Pancreatic Insufficiency (PI)

CompletedNCT00513682

Forest LaboratoriesCystic Fibrosis, Pancreatic Insufficiency

Start: 2007-07-31End: 2008-04-30Updated: 2017-03-16